A Mediterranean diet may help people with Alzheimer?s disease live longer than patients who eat a more traditional Western diet. The study is published in the September 11, 2007, issue of Neurology?, the medical journal of the American Academy of Neurology.
A small device implanted in the skull that detects oncoming seizures, then delivers a brief electrical stimulus to the brain to stop them is under study at the Medical College of Georgia.
In lifesaving procedures to open blocked heart arteries a key question has persisted for years: Is use of the more expensive drug, abciximab, justified over use of the less-expensive eptifibatide
The California Department of Food and Agriculture has issued an order to Organic Pastures Dairy Company to withdraw from retail distribution Grade A raw cream manufactured at their facility in Fresno, due to detection of Listeria monocytogenes bacteria.
Researchers have found surprising evidence that an antidepressant (citalopram) may perform as well as a commonly prescribed antipsychotic (risperidone) in the alleviation of severe agitation and psychotic symptoms of dementia. Researchers also found that the antidepressant was associated with “significantly lower” adverse side effects.
New research led by researchers at Warwick Medical School at the University of Warwick reveals that women?s health is much more at risk from sleep deprivation than men?s.
A new BC Cancer Agency study shows that newer drug therapies available since the 1990s, in particular aromatase inhibitors, improve the survival of women with metastatic breast cancer in the general population.
The rise in prevalence of asthma symptoms in English-speaking countries such as the United Kingdom and New Zealand has peaked and may even be in decline, researchers have found.
Researchers from the University of Glasgow revealed that the screening and treating middle-aged adults with a family history of coronary heart disease could prevent more than 4 in 10 premature heart attacks.
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the global specialty biopharmaceutical company, is disappointed that the overall NICE Guidance excludes newly diagnosed patients with mild AD, despite the revisions published which allow some discretion for clinicians in their reliance on the MMSE when dealing with exceptional patients.